← Leaderboards
Rubina A Heptulla
Baylor College Of Medicine
$4,982,785
Attributed
$4,982,785
Total exposure
17
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.2M · FY2005–13$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
Funding mix
By agency
NIH$4,982,785 · 17
By mechanism
R01$2,972,123 · 2
DP3$1,155,000 · 1
K23$650,275 · 1
M01$205,387 · 13
Top collaborators
No co-investigators on record.
Most similar at Baylor College Of Medicine
Same institution · by research overlap
- Luisa M Rodriguez$1,009,706
Others in their field
Top investigators on “Glucagon”
- David M Nathan · Massachusetts Institute Of Technology$119,524,803
- John M Lachin · George Washington University$118,921,924
- Ziad Nahas · Medical University Of South Carolina$22,722,368
- Klaus H. Kaestner · University Of Pennsylvania$22,239,542
- Alvin Carter Powers · Veterans Health Administration$18,850,608
- Ali Naji · University Of Pennsylvania$18,516,514
Research focus
GlucagonHyperglycemiaInsulinGlucoseAnalogIslet Amyloid PolypeptideDiabetes MellitusPramlintideProtocols DocumentationHypoglycemiaRandomizedHyperglucagonemiaGlucagon-Like Peptide 1Beta CellExenatideNew AgentsDoseInsulin-Dependent Diabetes MellitusGlycemic ControlGastroparesisChildhoodReportingAdultGastric Emptying
Grant awards (33)
Role of Oral vs Injectable Glucagon Suppressors$1,144,210
DP3 · FY2013 · DK · contact PI
Role of Oral vs Injectable Glucagon Suppressors$10,790
DP3 · FY2013 · DK · contact PI
Novel Glucagon Modulators and the Closed Loop System$398,497
R01 · FY2012 · DK · contact PI
Novel Glucagon Modulators and the Closed Loop System$386,339
R01 · FY2011 · DK · contact PI
Novel Glucagon Modulators and the Closed Loop System$408,771
R01 · FY2010 · DK · contact PI
Pediatric Type 1 Diabetes: Intervention Trials With Glucagon Suppressors$280,292
R01 · FY2010 · DK · contact PI
Pediatric Type 1 diabetes: Intervention Trials With Glucagon Suppressors$62,167
R01 · FY2010 · DK · contact PI
EXENATIDE (BYETTA) VS PRAMLINTIDE (SYMLIN)$19,838
M01 · FY2010 · RR · contact PI
DETEMIR: ROLE IN TYPE 1 DIABETES$15,642
M01 · FY2010 · RR · contact PI
Pediatric Type 1 diabetes: Intervention Trials With Glucagon Suppressors$12,232
R01 · FY2010 · DK · contact PI
Novel Glucagon Modulators and the Closed Loop System$351,626
R01 · FY2009 · DK · contact PI
Pediatric Type 1 diabetes: Intervention Trials With Glucagon Suppressors$263,956
R01 · FY2009 · DK · contact PI
CLINICAL TRIAL: THE ROLE OF EXENATIDE IN TYPE I DIABETES MELLITUS$10,072
M01 · FY2009 · RR · contact PI
DETEMIR: ROLE IN TYPE 1 DIABETES$8,592
M01 · FY2009 · RR · contact PI
Pediatric Type 1 diabetes: Intervention Trials With Glucagon Suppressors$264,749
R01 · FY2008 · DK · contact PI
CLINICAL TRIAL: CONTINUOUS SUBCUTANEOUS INFUSION OF PRAMLINTIDE AND INSULIN: A$10,262
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: POST-MEAL INSULIN DOSING WITH ADJUVANT PRE-MEAL PRAMLINTIDE IN C$5,131
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: THE ROLE OF EXENATIDE IN TYPE I DIABETES MELLITUS$4,908
M01 · FY2008 · RR · contact PI
Pediatric Type 1 diabetes: Intervention Trials With Glucagon Suppressors$270,729
R01 · FY2007 · DK · contact PI
New Therapeutic Targets in Pediatric Type 1 Diabetes$129,839
K23 · FY2007 · DK · contact PI
CONTINUOUS SUBCUTANEOUS INFUSION OF PRAMLINTIDE AND INSULIN: A RANDOMIZED DO$19,624
M01 · FY2007 · RR · contact PI
Pediatric Type 1 diabetes: Intervention Trials With Glucagon Suppressors$272,765
R01 · FY2006 · DK · contact PI
New Therapeutic Targets in Pediatric Type 1 Diabetes$129,839
K23 · FY2006 · DK · contact PI
GLUCOSE EXCURSIONS: ROLE OF AMYLIN AND GLUCAGON$8,375
M01 · FY2006 · RR · contact PI
THE EFFECT OF PROLONGED PRAMLINTIDE INFUSION IN PEDIATRIC DIABETES$2,482
M01 · FY2006 · RR · contact PI
New Therapeutic Targets in Pediatric Type 1 Diabetes$130,919
K23 · FY2005 · DK
THE EFFECT OF PROLONGED PRAMLINTIDE INFUSION IN PEDIATRIC DIABETES$22,530
M01 · FY2005 · RR
GLUCOSE EXCURSIONS: ROLE OF AMYLIN AND GLUCAGON$18,837
M01 · FY2005 · RR
EXAMINING THE EFFECT OF MIXING PRAMLINTIDE W/ HUMALOG IN TYPE I DIABETES$739
M01 · FY2005 · RR
New Therapeutic Targets in Pediatric Type 1 Diabetes$129,839
K23 · FY2004 · DK
Glucose Excursions: Role of Amylin and Glucagon$57,077
M01 · FY2004 · RR
Prolonged Pramlintide Infusion in Pediatric Diabetes$1,278
M01 · FY2004 · RR
New Therapeutic Targets in Pediatric Type 1 Diabetes$129,839
K23 · FY2003 · DK